Ligand Pharmaceuticals Incorporated (LGND) - Stock Analysis
Last updated: Jul 26, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Clear recent catalyst and guidance upside: on 2026-04-27 Ligand acquired XOMA Royalty, expanding the royalty portfolio to more than 200 assets and seven commercial products, expected to be immediately accretive, while management raised 2026 adjusted EPS guidance to $8.50-$9.50.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Breakout Holding ⢠Momentum Fading ⢠Support Test Support Level: $293.99-$295.92 Resistance Level: $305-$309 LGND is still holding above its late-June breakout and finding support near $294-$296, but lower highs since early July show fading momentum and a need to reclaim $305-$323 to restart the uptrend.
Sentiment & News
Key News Insights: ⢠Portfolio expansion ⢠Acquisition closed ⢠Earnings update LGND strengthened its long-term growth story by completing the XOMA Royalty acquisition, expanding its royalty portfolio above 200 assets, and setting up a Q2 earnings update on Aug. 6. #M&Aâ
AI Summary
LGND now looks less like a traditional biotech and more like a scaled royalty/IP compounder, with XOMA making earnings more visible and accretive, but the stock's rerating only holds if management can keep buying high-quality assets at disciplined prices and offset the convertible-driven dilution.
Description
Ligand Pharmaceuticals develops or acquires technologies that support pharmaceutical companies in discovering and developing medicines, commercializing a portfolio that spans oncology, infectious disease, endocrine and bone health, vaccines, and other specialty treatments. The company also partners on and licenses programs in clinical development targeting cancer, neurological, metabolic, cardiovascular, and other conditions, and it manufactures Captisol excipient materials. Founded in 1987, Ligand is headquartered in Emeryville, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 28 | May 5 | LGND | Ligand Pharmaceuticals Incorporated | Clear recent catalyst and guidance upside: on 2026-04-27 Ligand acquired XOMA Royalty, expanding the royalty portfolio to more than 200 assets and seven commercial products, expected to be immediately accretive, while management raised 2026 adjusted EPS guidance to $8.50-$9.50. | Closed | -0.0% |